ProgressImage ProgressImage
Alkem Laboratories Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code 539523 border-img ISIN Demat INE540L01014 border-img Book Value 1,142.87 border-img NSE Symbol ALKEM border-img Div & Yield % 0.82 border-img Market Cap ( Cr.) 65298.63 border-img P/E 29.5 border-img EPS 185.12 border-img Face Value 2
ParticularsMar 2025
()
Mar 2024
()
Mar 2023
()
Mar 2022
()
Mar 2021
()
Mar 2020
()
INCOME :       
Sales Turnover 8831.139747.729054.558829.817219.686677.08
Excise Duty 0.000.000.000.000.000.00
Net Sales 8831.139747.729054.558829.817219.686677.08
Other Income 698.23305.99266.29199.89190.0195.98
Stock Adjustments -56.6171.31-257.73360.90301.2933.69
Total Income 9472.7510125.029063.119390.607710.986806.75
EXPENDITURE :       
Raw Materials 2785.533878.633572.913926.792966.312584.25
Power & Fuel Cost 128.35123.85126.32129.53100.12106.08
Employee Cost 1723.091560.281516.221434.491158.721066.76
Other Manufacturing Expenses 509.57439.03361.12399.80280.51276.78
Selling & Administrative Expenses 1339.941608.761739.711438.801007.421158.51
Miscellaneous Expenses 131.84307.18103.5950.9471.7450.74
Less : Pre-operative Expenses Capitalised 0.000.000.000.000.000.00
Total Expenditure 6618.327917.737419.877380.355584.825243.12
Operating Profit 2854.432207.291643.242010.252126.161563.63
Interest 76.1181.9186.4037.9042.9338.71
Gross Profit 2778.322125.381556.841972.352083.231524.92
Depreciation 283.61244.35229.85218.98198.93186.84
Profit Before Tax 2494.711881.031326.991753.371884.301338.08
Tax 261.10333.28227.52303.82331.83246.95
Fringe Benefit tax 0.000.000.000.000.000.00
Deferred Tax -47.28-199.40-35.00-91.70-132.61-173.29
Reported Net Profit 2280.891747.151134.471541.251685.081264.42
Extraordinary Items 4.20-54.86-10.241.8216.493.07
Adjusted Net Profit 2276.691802.011144.711539.431668.591261.35
Adjustment below Net Profit 0.000.000.000.000.00-73.21
P & L Balance brought forward 8640.887431.776823.395700.624350.323517.81
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 502.17538.04526.09418.48334.78358.70
P & L Balance carried down 10419.608640.887431.776823.395700.624350.32
Dividend 0.000.000.000.000.00263.05
Preference Dividend 0.000.000.000.000.000.00
Equity Dividend % 2250.002000.002500.001700.001500.001250.00
Dividend Per Share(Rs) 45.0040.0050.0034.0030.0025.00
Earnings Per Share-Unit Curr 190.79146.1494.90128.92140.95105.76
Earnings Per Share(Adj)-Unit Curr 190.79146.1494.90128.92140.95105.76
Book Value-Unit Curr 1030.68882.86782.09731.38637.87525.34
Book Value(Adj)-Unit Curr 1030.68882.86782.09731.38637.87525.34
`

ATTENTION INVESTORS : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day ...Issued in the interest of investors.  Prevent Unauthorized Transactions in your demat account Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......issued in the interest of investors.   KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Investor Protection and Arbitration Exchange Circulars and Rules - NSE BSE

Filing of complaints on SCORES – Easy & quick   |    Advisory for Investors   |    AP Details - NSE   |    AP Details - BSE   |    AP Details - MCX
KYC Process Flow   |    Investor Grievance Redressal Process Flow   |   Online Grievance Redressal   |    Voluntary Freezing/Blocking of Trading Account   |    Website Accessibility Statement

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing.

x
x
×
Let's Chat
imsl-img
close
refresh